Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 78, Issue 2, Pages 323-332Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2017.10.012
Keywords
biologic therapy; effectiveness; psoriasis; real-world; registry; safety; systemic therapy
Categories
Funding
- Corrona LLC
- AbbVie
- Boehringer Ingelheim
- Celgene
- Valeant
- Merck
- Eli Lilly and Company
- Novartis Pharmaceutical Corporation
- Amgen
- AstraZeneca
- Bristol-Myers Squibb
- Crescendo
- Genentech
- GlaxoSmithKline
- Horizon Pharma USA
- Janssen
- Momenta Pharmaceuticals
- Novartis
- Pfizer
- Roche
- UCB
Ask authors/readers for more resources
Background: Psoriasis is an immunodysregulatory inflammatory disease associated with comorbidities affecting quality of life. With the advent of new treatments, there is growing need to assess the long-term safety and efficacy of treatments in a real-world setting. Objective: The objective of the Corrona Psoriasis Registry is to study the comparative safety and efficacy of Food and Drug Administration-approved biologic treatments. Methods: A cross-sectional study of patients enrolled in the registry, who initiated or switched to a systemic therapy at enrollment or previous 12 months. Descriptive characteristics (demographics, clinical and patient-reported outcomes, comorbidities, and treatment history) were examined at registry enrollment. Results: As of October 1, 2016, there were 1942 patients enrolled in the registry: 23% on apremilast, 4% on other nonbiologic systemic medications, 25% on interleukin (IL) 17A inhibitors, 22% on an IL-12/23 inhibitor, and 26% on tumor necrosis factor inhibitors. Overall, mean disease duration was 15.6 years, and 40% had a concurrent psoriatic arthritis diagnosis. About 66% had >3% body surface area involvement and 49% had a moderate or severe Investigator Global Assessment. Limitations: Selection and channeling bias can result in potential confounding that needs to be addressed in modeled analyses. Conclusion: This disease-based registry cohort represents a population exposed to multiple therapies, long disease duration, and multiple comorbidities and can be used to examine comparative safety and efficacy of various therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available